Synthetic Biology's Defense Dollars: Signals and Perceptions
By Dr. Filippa Lentzos,
PLOS Blogs
| 12. 24. 2015
Untitled Document
Synthetic biology is swimming in defense dollars. The most recent figures available on US trends in synthetic biology research funding indicate that two thirds of the $200 million invested in 2014 came from the Department of Defense or its research agency DARPA. While many scientists see military money as just another source of funding on par with NIH or NSF funding—after all, the majority of the funds are for basic science without security classification and publication restrictions—there are good reasons not to brush it off. One of these is the perception of the field to outsiders.
From an international security perspective, the extensive influx of military funding can be perceived as threatening to analysts in other countries following these developments. The US Department of Defense declared just over $655 million on national biodefence research in 2014. Synthetic biology research appears, therefore, to make up about a fifth of the biodefence budget. DARPA aims not only to develop radically new, game-changing technologies for national security in order to maintain US technological supremacy, it also aims to create technological surprise...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...